Compare · ELVN vs NVO
ELVN vs NVO
Side-by-side comparison of Enliven Therapeutics Inc. (ELVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, ELVN is up 133.6% and NVO is down 34.2% - ELVN leads by 167.8 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for ELVN).
- NVO has more recent analyst coverage (25 ratings vs 7 for ELVN).
- Company
- Enliven Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $44.22+0.88%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- +24.34%
- +13.32%
- 1Y return
- +133.57%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 5
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELVN
- SEC Form 4 filed by Collins Helen Louise
- SEC Form PRE 14A filed by Enliven Therapeutics Inc.
- SEC Form 4 filed by Collins Helen Louise
- SEC Form 4 filed by Collins Helen Louise
- SEC Form 4 filed by Enliven Therapeutics Inc.
- CHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)
- SEC Form S-8 filed by Enliven Therapeutics Inc.
- SEC Form 10-K filed by Enliven Therapeutics Inc.
- Enliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S